SWOG Cancer Research Network
@SWOG
Followers
14K
Following
15K
Media
2K
Statuses
15K
SWOG Cancer Research Network runs publicly funded clinical trials that have saved 3 million+ years of life. Founded by the National Cancer Institute in 1956.
United States
Joined January 2012
The @SWOG S1501 trial has reopened and is enrolling patients w HER2+ #breastcancer to its observation-only arm (Arm 3). Arms 1 & 2 are closed, but patients already on these arms continue protocol-specified therapy. PI: Justin Floyd, DO, @CancerCareIL.
0
0
2
A phase 1/2 trial in #mCRPC found adding carboplatin to cabazitaxel improved PFS & OS in patients whose tumors had an AVPC-MS aggressive variant signature. @SWOG S2312 puts this to a phase 3 test. TM chairs: @djmcconkey & Amir Goldkorn, MD.
0
1
3
Our @SWOGChair's blog:.It’s Hard to Believe, but Coming Next Tuesday: Fall Meeting Registration.On July 15th, online registration opens for the @SWOG fall 2025 group meeting in Chicago, September 18th - 20th. Plan now to be there then.
0
1
3
Our #TranslationalMedicine Link of the Week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD:.ESMO-ESTRO Framework for Assessing the Interactions and Safety of Combining Radiotherapy with Targeted Cancer Therapies or Immunotherapy .
0
1
3
Phase 3 @SWOG S2312 randomizes patients with metastatic castrate-resistant #ProstateCancer to cabazitaxel w or w/out carboplatin. All are screened for an aggressive variant signature (AVPC-MS), used to stratify. Co-PIs: @aaparicioMD & @vanderweelemd.
0
0
3
DART (@SWOG S1609) rare cancer trial results of dual-ICI therapy in the pancreatic neuroendocrine neoplasm (PNEN) cohort, just published in @jitcancer: .Clinical benefit rate (incl stable disease >6 mo + objective response) of 26%, w durable benefit >2 yrs in 3 of 19 patients.
New #JITC article: Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort @youngkwangchae @anup_kasi @walshauserMD @EdgarEGK @Dra_Cells @EladSharonMD
0
2
4
Do you have T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that didn’t get better with treatment — or went away and came back? Ask your doctor about #ClinicalTrial S1905. 1-800-4-CANCER. #ALLsm #leusm
0
0
3
S2312 trial of cabazitaxel w/wo carboplatin in #mCRPC. Starting cabazitaxel dose is 25 mg/m^2, but providers can select 20 mg/m^2 (before randomization) to reflect FDA approval of that lower dose in 2017. Alliance Champion: @DrMohammadAtiq1 @UChicagoMed.
0
0
5
RT @KUcancercenter: Testing for certain features in cancer (biomarkers) can tell doctors about what’s causing it to grow. The #myeloMATCH s….
0
3
0
S2013 #ICHECKIT is reopened and enrolling at #NCORP sites. Developing a risk prediction model for #irAEs from ICI-based therapy. Also exploring the association of dietary fiber intake with severe #irAEs. @eaonc Champion: @diwakardavar @UPMCHillmanCC
0
1
4
Our @SWOGChair blog:.Happy Independence Day.I hope you and your loved ones enjoy whatever celebration, fireworks, picnic, or just simple rest and relaxation you have planned. I know I will!.
0
1
3
Our #TranslationalMedicine Link of the Week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD (a day early this week, in recognition of the U.S. holiday):.Aurora Kinases Signaling in Cancer: From Molecular Perception to Targeted Therapies.
0
1
3
S2013 #ICHECKIT is enrolling again, but at #NCORP sites only. Enrolling patients starting ICI + chemo for #NSCLC, small-cell #lungcancer, #TNBC, or gastroesophageal #cancer. TM chair: @SiwenONC @HuntsmanCancer.
0
3
6
#Prostatecancer study S2312 compares usual cabazitaxel treatment to chemo with cabazitaxel and carboplatin. It also uses tumor testing to identify aggressive variant prostate cancer. 1-800-4-CANCER. #pcsm
0
1
4
Many people with #cancer are treated with drugs called immune checkpoint inhibitors. #ClinicalTrial S2013 #ICHECKIT may help us predict who is at risk for side effects from these drugs. Learn more: Or call 1-800-4-CANCER. Ask about S2013.
0
4
4
Site feedback let the team adjust the protocol & complete this $ navig study. Addressing Challenges in Research Aimed at Reducing Financial Toxicity Among Cancer Patients & Caregivers: An Example From the CREDIT Study (@SWOG S1912CD), via @CancerControl_
0
0
3
Trial S2312 asks if testing for aggressive variant #prostatecancer (AVPC-MS) can help guide treatment. Enrolling patients with #mCRPC previously treated w docetaxel, but no prior cabazitaxel or carboplatin. Biostatistician: Cathy M. Tangen, DrPH @fredhutch.
0
1
2
S2013 #ICHECKIT is enrolling again, but at #NCORP sites only. Enrolling patients starting ICI + chemo for #NSCLC, small-cell #lungcancer, #TNBC, or gastroesophageal #cancer. Co-PI: Alexander Z. Wei, MD @ColumbiaCancer
0
0
4